Alexion Pharmaceuticals, Inc. v. Amgen Canada Inc.
Federal Court upheld Alexion’s 810 Patent, finding Amgen failed to prove anticipation or obviousness and granting infringement relief for BEKEMV eculizumab.
- Anticipation
- Obviousness
- Claims construction
- Injunction
- Delivery up/destroy
- Patent medicines (notice of compliance) regulations